PMID- 23497344
OWN - NLM
STAT- MEDLINE
DCOM- 20130809
LR  - 20211021
IS  - 1479-5876 (Electronic)
IS  - 1479-5876 (Linking)
VI  - 11
DP  - 2013 Mar 7
TI  - Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal 
      squamous cell carcinoma.
PG  - 59
LID - 10.1186/1479-5876-11-59 [doi]
AB  - BACKGROUND: Protein tyrosine kinase 6 (PTK6), also known as breast tumor kinase 
      (Brk), was a nonreceptor tyrosine kinase containing SH3, SH2, and tyrosine kinase 
      catalytic domains. The deregulated expression of PTK6 was observed in various 
      human cancers. However, little was known about PTK6 expression and its 
      clinicopathological significance in human laryngeal squamous cell carcinoma 
      (LSCC). MATERIALS: PTK6 expression was evaluated in 7 pairs of surgically 
      resectable laryngeal tissues by Western blotting and in 13 pairs of surgically 
      resectable laryngeal tissues by reverse transcription-PCR (RT-PCR). Using 
      immunohistochemistry, we performed a retrospective study of the PTK6 expression 
      levels on 134 archival LSCC paraffin-embedded samples. Prognostic outcomes 
      correlated with PTK6 were examined using Kaplan-Meier analysis and Cox 
      proportional hazards model. RESULTS: The PTK6 expression level was lower in LSCC 
      tissues than in the adjacent noncancerous epithelial laryngeal tissues by Western 
      blots and RT-PCR. By immunohistochemical analysis, we observed high expression of 
      PTK6 in 25 of 76 (32.9%) adjacent noncancerous epithelial laryngeal tissues and 
      in 39 of 134 (29.1%) of LSCC, respectively. Multivariate analysis demonstrated 
      that pN status and the expression level of PTK6 (P < 0.05) were independent and 
      significant prognostic factors. In the primary LSCC category, median DFS (disease 
      free survival) of high, medium and low PTK6 expression patients were 88.5 months 
      ,74.5 months and 49.0 months (log-rank test, P = 0.002); median OS (overall 
      survival) of high, medium and low PTK6 expression patients were 88.5 months 
      ,76.3 months and 65.7 months (log-rank test, P = 0.002). Reduced cytoplasmic PTK6 
      expression in LSCC was significantly associated with late pN status (P =0.005, 
      r = 0.27), advanced pTNM stages (III and IV) (P =0.027, r = 0.147), and poor 
      differentiated LSCC (P <0.0001, r = 0.486). In adjacent paracancerous laryngeal 
      epithelial samples, median DFS of high, medium and low PTK6 expression patients 
      were 92.6 months ,75.6 months and 48.5 months (log-rank test, P = 0.020); median 
      OS of high, medium and low PTK6 expression patients were 92.9 months ,78.9 months 
      and 74.6 months (log-rank test, P = 0.042). CONCLUSION: The present findings 
      indicated that cytoplasmic PTK6 expression is a potential prognostic factor for 
      survival in LSCC patients. High expression of PTK6 was associated with favorable 
      OS and DFS in LSCC patients.
FAU - Liu, Xue-Kui
AU  - Liu XK
AD  - State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer 
      Centre, Guangzhou, Guangdong, China.
FAU - Zhang, Xin-Rui
AU  - Zhang XR
FAU - Zhong, Qian
AU  - Zhong Q
FAU - Li, Man-Zhi
AU  - Li MZ
FAU - Liu, Zhi-Min
AU  - Liu ZM
FAU - Lin, Zhi-Rui
AU  - Lin ZR
FAU - Wu, Di
AU  - Wu D
FAU - Zeng, Mu-Sheng
AU  - Zeng MS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130307
PL  - England
TA  - J Transl Med
JT  - Journal of translational medicine
JID - 101190741
RN  - 0 (DNA Primers)
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (PTK6 protein, human)
SB  - IM
MH  - Aged
MH  - Base Sequence
MH  - Blotting, Western
MH  - Carcinoma, Squamous Cell/*metabolism
MH  - DNA Primers
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*metabolism
MH  - Male
MH  - Neoplasm Proteins/*metabolism
MH  - Prognosis
MH  - Protein-Tyrosine Kinases/*metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
PMC - PMC3599503
EDAT- 2013/03/19 06:00
MHDA- 2013/08/10 06:00
PMCR- 2013/03/07
CRDT- 2013/03/19 06:00
PHST- 2012/09/23 00:00 [received]
PHST- 2013/03/03 00:00 [accepted]
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2013/08/10 06:00 [medline]
PHST- 2013/03/07 00:00 [pmc-release]
AID - 1479-5876-11-59 [pii]
AID - 10.1186/1479-5876-11-59 [doi]
PST - epublish
SO  - J Transl Med. 2013 Mar 7;11:59. doi: 10.1186/1479-5876-11-59.